Sequence characterization and molecular modeling of clinically relevant variants of the SARS-CoV-2 main protease
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
The SARS-CoV-2 main protease (M pro ) is essential to viral replication and cleaves highly specific substrate sequences, making it an obvious target for inhibitor design. However, as for any virus, SARS-CoV-2 is subject to constant selection pressure, with new M pro mutations arising over time. Identification and structural characterization of M pro variants is thus critical for robust inhibitor design. Here we report sequence analysis, structure predictions, and molecular modeling for seventy-nine M pro variants, constituting all clinically observed mutations in this protein as of April 29, 2020. Residue substitution is widely distributed, with some tendency toward larger and more hydrophobic residues. Modeling and protein structure network analysis suggest differences in cohesion and active site flexibility, revealing patterns in viral evolution that have relevance for drug discovery.
Article activity feed
-
SciScore for 10.1101/2020.05.15.097493: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources Open reading frames in these high-quality full genomes were compared with a reference Mpro nucleotide sequence (WT, RefSeq: NC 045512.2, loc: 10,055–10,972), to extract Mpro sequences of at least 80% similarity using a script written in Python v3.7.0 (35). Pythonsuggested: (IPython, RRID:SCR_001658)Full genome alignments were performed using MUSCLE (14) on the complete set of non-synonymous Mpro mutants as well as reference WT, bat, and pangolin sequences. MUSCLEsuggested: (MUSCLE, RRID:SCR_011812)Trees were generated in MEGA X (15), using the Neighbor-Joining method (37); a bootstrap test … SciScore for 10.1101/2020.05.15.097493: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
NIH rigor criteria are not applicable to paper type.Table 2: Resources
Software and Algorithms Sentences Resources Open reading frames in these high-quality full genomes were compared with a reference Mpro nucleotide sequence (WT, RefSeq: NC 045512.2, loc: 10,055–10,972), to extract Mpro sequences of at least 80% similarity using a script written in Python v3.7.0 (35). Pythonsuggested: (IPython, RRID:SCR_001658)Full genome alignments were performed using MUSCLE (14) on the complete set of non-synonymous Mpro mutants as well as reference WT, bat, and pangolin sequences. MUSCLEsuggested: (MUSCLE, RRID:SCR_011812)Trees were generated in MEGA X (15), using the Neighbor-Joining method (37); a bootstrap test (38) of 1000 replicates was performed, and distances were calculated using the Maximum Composite Likelihood model (38). MEGAsuggested: (Mega BLAST, RRID:SCR_011920)Initial variant protein structures were predicted using MODELLER 9.23 (30), using the 6Y2E structure as a template; three rounds of annealing and MD refinement were performed using the “slow” optimization level for each. MODELLERsuggested: (MODELLER, RRID:SCR_008395)Table of Contents: Contentssuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-